# EDGAR Filing Document

**Accession Number:** 0000728387
**File Stem:** 0001437749-23-002010
**Filing Date:** 2023-1
**Character Count:** 9564
**Document Hash:** 795c7dcb2b01ad508551069204e61aa8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-23-002010.hdr.sgml**: 20230130

**ACCESSION NUMBER**: 0001437749-23-002010

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230127

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230130

**DATE AS OF CHANGE**: 20230130

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Isoray, Inc.
- **CENTRAL INDEX KEY:** 0000728387
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 411458152
- **STATE OF INCORPORATION:** MN
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33407
- **FILM NUMBER:** 23565318

**BUSINESS ADDRESS:**
- **STREET 1:** 350 HILLS STREET,
- **STREET 2:** SUITE 106
- **CITY:** RICHLAND
- **STATE:** WA
- **ZIP:** 99354
- **BUSINESS PHONE:** (509) 375-1202

**MAIL ADDRESS:**
- **STREET 1:** 350 HILLS STREET,
- **STREET 2:** SUITE 106
- **CITY:** RICHLAND
- **STATE:** WA
- **ZIP:** 99354

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IsoRay, Inc.
- **DATE OF NAME CHANGE:** 20050805

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CENTURY PARK PICTURES CORP
- **DATE OF NAME CHANGE:** 19920703

isr20230127_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

 **WASHINGTON, DC 20549**

**FORM **8-K**

**CURRENT REPORT PURSUANT TO** 

**SECTION 13 OR 15(D) OF THE** 

**SECURITIES EXCHANGE ACT OF 1934**

---

| | | |
|:---|:---|:---|
| Date of report (Date of earliest event reported): January 27, 2023 | Date of report (Date of earliest event reported): January 27, 2023 | Date of report (Date of earliest event reported): January 27, 2023 |
| **<u>Isoray, Inc.</u>**<br> (Exact Name of Registrant as Specified in Charter) | **<u>Isoray, Inc.</u>**<br> (Exact Name of Registrant as Specified in Charter) | **<u>Isoray, Inc.</u>**<br> (Exact Name of Registrant as Specified in Charter) |
| **<u>Delaware</u>**<br> (State or Other Jurisdiction<br> of Incorporation) | **<u>001-33407</u>**<br> (Commission<br> File Number) | **<u>41-1458152</u>**<br> (IRS Employer<br> Identification No.) |

---

**<u>350 Hills Street, Suite 106</u><u>, **<u>Richland</u>**, **<u>Washington</u> <u>99354</u>**</u>**

(Address of Principal Executive Offices) (Zip Code)

**<u>(**<u>509</u>**) **<u>375-1202</u>**</u>**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.001 par value | ISR | NYSE American |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On January 27, 2023, the Company held its adjourned Fiscal 2023 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the stockholders of the Company voted on the following proposal and cast their votes as described below. Of the 142,112,766 common shares outstanding and entitled to vote at the Annual Meeting, 103,856,525 common shares (or 73.08%), constituting a quorum, were represented in person or by proxy at the Annual Meeting.

The voting results on the proposal are set forth below.

<u>Proposal One</u> <u>–</u> <u>The Certificate Amendment Proposal</u>. Proposal One was to approve an amendment to the Company's Certificate of Incorporation to increase the total number of authorized shares of Common Stock to 750,000,000. The votes for this proposal were:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 71,844,322 | 14,571,252 | 948,682 | 16,492,269 |

---

Proposal One was therefore approved by a majority of the Company's issued and outstanding shares of Common Stock and allows the Company to proceed with the closing of the transaction contemplated by the Agreement and Plan of Merger dated September 27, 2022, and previously disclosed in the Company's Form 8-K filed with the Securities and Exchange Commission (the "SEC") on September 28, 2022.

**Item 7.01 Regulation FD Disclosure**

On January 30, 2023, the Company issued a press release announcing the convening of the Annual Meeting and the results of the votes, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information furnished in this Item 7.01 shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934, as amended (the "1934 Act"), and shall not be deemed incorporated by reference in any filing with the SEC, whether or not filed under the Securities Act of 1933, as amended, or the 1934 Act, regardless of any general incorporation language in such document.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

99.1 [Press Release dated January 30, 2023.](ex_469357.htm)

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 30, 2023

Isoray, Inc., a Delaware corporation

By: <u>/s/ Lori A. Woods</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lori A. Woods, CEO

## Exhibit 99.1

**Exhibit 99.1**

![ex_469357img001.jpg](ex_469357img001.jpg)

**Isoray Announces Results of Fiscal 2023** 

**Annual Meeting of Stockholders**

*Stockholders Approve Proposal One Clearing Way for Consummation of Merger*

RICHLAND, WASHINGTON – January 30, 2023 – <u>Isoray, Inc.</u> (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced the results of its adjourned Fiscal 2023 Annual Meeting of Stockholders which was held on January 27, 2023.

The stockholders approved Proposal One which amends the Company's Certificate of Incorporation to increase the total number of authorized shares of Common Stock to 750,000,000 shares. Proposal One, which required an affirmative vote of a majority of the outstanding common stock for passage, received 71,844,322 share votes in favor of the proposal which represents 50.55% of the total shares outstanding. The passage of Proposal One allows the Company to proceed with the proposed merger with Viewpoint Molecular Targeting, Inc. The Company anticipates completing the merger in the near future.

**Contacts**

Investor Relations: Mark Levin (501) 255-1910

Media and Public Relations: Sharon Schultz (302) 539-3747

**About Isoray**

Isoray, Inc. is a medical technology company pioneering advanced treatment applications and devices to deliver targeted internal radiation treatments for cancers throughout the body. Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting <u>www.isoray.com</u>. Follow us on <u>LinkedIn</u> and <u>Twitter</u>.

**Safe Harbor Statement**

Statements in this news release about Isoray's future expectations, including: the timing of the completion of the proposed merger with Viewpoint Molecular Targeting, Inc., and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing Isoray, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as the timing and closing of the proposed merger with Viewpoint Molecular Targeting, Inc., including whether all closing conditions are satisfied or waived, whether the merger is completed and, if so, whether the anticipated benefits of the merger are realized. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.